Researchers awarded prize for stem cell research

Article

The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3RS) has awarded its annual prize to a project exploring the use of stem cells for treating glaucoma and other eye diseases.

The UK's National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3RS) has awarded its annual prize to a project exploring the use of stem cells for treating retina diseases and other ocular conditions.

Dr Keith Martin and Thomas Johnson of the University of Cambridge's Centre for Brain Repair in the UK are investigating using stem cells as neuroprotectants in damaged retinas. The team implanted the stem cells into explanted tissue from rats' eyes that had been kept alive in the laboratory instead of transplanting the cells into the retinas of anaesthetized animals, as is the traditional method. Because multiple layers of tissue can be obtained from a single animal, Dr Martin's method reduced the number of animals used in experiments to an eighth.

The £10,000 (approx €11,400) NC3RS prize is sponsored by pharmaceutical company GlaxoSmithKline, and was awarded by Phil Willis MP, Chair of the House of Commons Innovation, Universities, Science and Skills Select Committee, at a ceremony in London. Two highly commended prizes were also awarded.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.